Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 12,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001296569-26-000002 · wk-form4_1781640992.xml · derivative · entry 2 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001296569-26-000002 · wk-form4_1781640992.xml · nonDerivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,481 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001296569-25-000005 · wk-form4_1750111578.xml · derivative · entry 2 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001296569-25-000005 · wk-form4_1750111578.xml · nonDerivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,216 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000011 · wk-form4_1718050106.xml · derivative · entry 2 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000011 · wk-form4_1718050106.xml · nonDerivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,175 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037498 · doc4.xml · derivative · entry 2 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037498 · doc4.xml · nonDerivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-22-034065 · doc4.xml · derivative · entry 2 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034065 · doc4.xml · nonDerivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| September 16, 2021 Filed Sep 24, 2021 21:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $26.37 | $0.00 |
DisclosureSEC source: 0001209191-21-057654 · doc4.xml · derivative · entry 1 Drapeau Anne S · CIK 0001296569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-09-15 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on September 16, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.